Status:
UNKNOWN
Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection
Lead Sponsor:
The Seventh Affiliated Hospital of Sun Yat-sen University
Conditions:
Tumor
COVID-19
Eligibility:
All Genders
18-85 years
Brief Summary
The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main question...
Eligibility Criteria
Inclusion
- Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31.
- COVID-19 was confirmed by antigen testing or nucleic acid testing.
- Tumor was confirmed by pathology.
- Patients received systemic antitumor therapy after infected with COVID-19.
Exclusion
- COVID-19 was not confirmed by antigen testing or nucleic acid testing
- Tumor was not confirmed by pathology
- Patients did not receive systemic antitumor therapy
- Patients died before receiving systemic antitumor therapy
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06006845
Start Date
December 1 2022
End Date
August 31 2024
Last Update
August 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seventh Affiliated Hospital, Sun Yat-sen University
Shenzhen, Guangdong, China, 518107